Xtant Medical Holdings (Xtant Medical Holdings) Risk Assessment

View and export this data going back to 2007. Start your Free Trial

What is Xtant Medical Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Xtant Medical Holdings is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Xtant Medical Holdings's Risk Assessment

For the Medical Devices subindustry, Xtant Medical Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xtant Medical Holdings's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Xtant Medical Holdings's Risk Assessment falls into.

Xtant Medical Holdings (AMEX:XTNT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Xtant Medical Holdings Risk Assessment Related Terms

Thank you for viewing the detailed overview of Xtant Medical Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Xtant Medical Holdings (Xtant Medical Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xtant Medical Holdings Inc (AMEX:XTNT) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

XMS:Germany

Address

664 Cruiser Lane, Belgrade, MT, USA, 59714

Website

http://www.xtantmedical.com

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.

Executives

Kevin D Brandt	officer: VP & Chief Commercial Officer	11621 RESEARCH CIRCLE, ALACHUA FL 32615
Lori D Mitchell-keller	director	664 CRUISER LANE, BELGRADE MT 59714
Jonn R. Beeson	director	664 CRUISER LANE, BELGRADE MT 59714
Scott C Neils	officer: Interim CFO	664 CRUISER LANE, BELGRADE MT 59714
Mark A. Schallenberger	officer: Chief Operations Officer	664 CRUISER LANE, BELGRADE MT 59714
Sean E Browne	officer: President and CEO	664 CRUISER LANE, BELGRADE MT 59714
Stavros G. Vizirgianakis	director	1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Orbimed Rof Ii Llc	director, 10 percent owner	601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
Greg Jensen	officer: VP, Finance and Interim CFO	664 CRUISER LANE, BELGRADE MT 59714
Ronald G. Berlin	officer: VP & Chief Operations Officer	664 CRUISER LANE, BELGRADE MT 59714
Kathie J. Lenzen	officer: SVP Fiance & Admin. & CFO	664 CRUISER LANE, BELGRADE MT 59714
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Matthew Rizzo	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael Eggenberg	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert Mcnamara	director	C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750